On World Alzheimer's Day, we are extending our dedication to be there for families and loved ones living day-to-day time with Alzheimer’s through initiatives like Take 1 Second, said Gavin Corcoran, MD, Chief Medical Officer. We support the campaign’s initiatives to ease the burden on caregivers. We also remain committed to offering new therapeutic options for all those with moderate to severe Alzheimer’s disease, such as for example NAMZARIC .This personalized medicine approach might accelerate drug development in ALS and other life-threatening disorders. Related StoriesArtemisinin and the fight against malaria: an interview with Dr. An interview with Professor Lesley Jones The partnership will integrate Denovo's pharmacogenomic technology in to the evaluation of biological samples obtained from expanded gain access to programs that ALS-ETF sponsors. By determining genomic biomarkers that correlate with sufferers' responsiveness to treatment, the partners seek to recognize appropriate patient subsets for the carry out of subsequent trials. Dr. Wen Luo, Chief Scientific Officer for Denovo Biomarkers, observed, ‘This partnership leverages the mission of ALS-ETF and the broad utility of our system. We hope our combined efforts shall result in better, more targeted treatments for ALS.